

VICURON PHARMACEUTICALS INC
 Form 4
 February 08, 2005

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
HORNER GEORGE F III

2. Issuer Name and Ticker or Trading Symbol
VICURON PHARMACEUTICALS INC [MICU]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
455 S. GULPH ROAD, SUITE 305
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
02/07/2005

Director 10% Owner
 Officer (give title below) Other (specify below)
President & CEO

KING OF PRUSSIA, PA 19406
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	02/07/2005		S(1)	10,000 D	\$ 18	51,250	D
Common Stock	02/07/2005		S(1)	2,000 D	\$ 18.0525	49,250	D
Common Stock	02/07/2005		S(1)	2,000 D	\$ 18.0935	47,250	D
Common Stock	02/07/2005		S(1)	3,700 D	\$ 18.14	43,550	D
Common Stock	02/07/2005		S(1)	2,000 D	\$ 18.179	41,550	D

Edgar Filing: VICURON PHARMACEUTICALS INC - Form 4

Common Stock	02/07/2005	S ⁽¹⁾	800	D	\$ 18.2053	40,750	D
Common Stock	02/07/2005	S ⁽¹⁾	2,000	D	\$ 18.1723	38,750	D
Common Stock	02/07/2005	S ⁽¹⁾	2,000	D	\$ 18.1324	36,750	D
Common Stock	02/07/2005	S ⁽¹⁾	23,500	D	\$ 18.01	13,250	D
Common Stock	02/07/2005	S ⁽¹⁾	2,000	D	\$ 18.1095	11,250	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 0.4	02/07/2005		M	50,000	<u>(2)</u>	12/08/2007	Common Stock	50,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HORNER GEORGE F III 455 S. GULPH ROAD SUITE 305 KING OF PRUSSIA, PA 19406	X		President & CEO	

Signatures

/S/ PETER T. HEALY, ESQ. ATTORNEY-IN-FACT FOR GEORGE F.
HORNER III

02/08/2005

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 24, 2004.
 - (2) Subject to continued service, the option vests as to 25% of the underlying shares 12 months after the date of grant and the balance of 75% vests in 36 equal monthly installments commencing 13 months after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.